![Puma Biotechnology, Pierre Fabre enter into license agreement to develop and commercialize NERLYNX in Europe - Pharmaceutical Business review Puma Biotechnology, Pierre Fabre enter into license agreement to develop and commercialize NERLYNX in Europe - Pharmaceutical Business review](https://pharmaceutical-business-review.com/wp-content/uploads/2019/04/medic-563423_960_720.jpg)
Puma Biotechnology, Pierre Fabre enter into license agreement to develop and commercialize NERLYNX in Europe - Pharmaceutical Business review
![Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire](https://mms.businesswire.com/media/20190401005264/en/396178/5/puma_logo_JPEG.jpg?download=1)
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
![PUMA SE on Twitter: "Welcome to the PUMA family Pierre-Ambroise Bosse! #ForeverFaster #NoMatterWhat @pa_bosse http://t.co/dBnGf8Wm6u" PUMA SE on Twitter: "Welcome to the PUMA family Pierre-Ambroise Bosse! #ForeverFaster #NoMatterWhat @pa_bosse http://t.co/dBnGf8Wm6u"](https://pbs.twimg.com/media/CRSSQbsWcAEr-GW.png)